SS
TBPH icon

Sunbelt Securities’s Theravance Biopharma TBPH Stock Holding History

Sunbelt Securities’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$179 Hold
11
– – ﹤0.01% 2533
2025
Q4 		$206 Hold
11
– – ﹤0.01% 2429
2025
Q3 		$161 Buy
+11
New +$139 ﹤0.01% 2445

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sunbelt Securities's TBPH Position: Q1 2026 in Review

Sunbelt Securities held its Theravance Biopharma (TBPH) position steady in Q1 2026 at 11 shares worth $179. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

Sunbelt Securities first reported a position in TBPH in Q3 2025 and has held it in 3 quarters since. The position peaked at $206 in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Sunbelt Securities held 11 shares of Theravance Biopharma worth $179 as of Q1 2026.
  • Sunbelt Securities left its Theravance Biopharma share count unchanged in Q1 2026.
  • Theravance Biopharma made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2533 holding.
  • Sunbelt Securities first reported a position in Theravance Biopharma in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Theravance Biopharma position peaked at $206 in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.